T1	intervention 0 17	Topical silymarin
T2	condition 51 72	acute radiodermatitis
T3	control 652 659	placebo
T4	No-of-participants 692 697	Forty
T5	duration 877 884	5Â weeks
T6	outcome-Measure 886 910	Radiodermatitis severity
T7	outcome-Measure 1115 1147	median NCI-CTCAE and RTOG scores
T8	outcome 1253 1283	scores increased significantly
